Alira Health Unveils 2024 Report on Antibody-Drug Conjugates Market
03 déc. 2024 09h00 HE
|
Alira Health
Gain comprehensive insights into the ADC market with the Alira Health 2024 Global Antibody-Drug Conjugates Report's in-depth analysis.
MacroGenics to Participate in Upcoming Investor Conference
02 déc. 2024 16h30 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Dec. 02, 2024 (GLOBE NEWSWIRE) -- -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative...
Araris Biotech Publishes Foundational Science Behind its Novel Antibody-Drug Conjugate Platform in ChemBioChem
12 nov. 2024 08h00 HE
|
Araris Biotech
First characterization of its novel conjugation technology for creating stable, well-defined ADCs with linkers that enable payload attachment to native, unmodified antibodies at a universally...
Vaccinex Provides Update on ActivMAb® Platform: Multiple Project Deals and Presentation at SITC
07 nov. 2024 08h30 HE
|
Vaccinex, Inc.
Partnerships will employ Vaccinex’s ActivMAb® tech. Successful antibody discovery campaigns for cancer immunotherapy to be presented at SITC Nov 9, 2024.
MacroGenics to Participate in Upcoming Investor Conferences
06 nov. 2024 16h30 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Nov. 06, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative monoclonal...
MacroGenics Provides Update on Corporate Progress, Third Quarter 2024 Financial Results
05 nov. 2024 16h01 HE
|
MacroGenics, Inc.
Strengthened financial position resulting from recently announced MARGENZA® transaction and previously announced receipt of milestone payment from Incyte related to advancement of ZYNYZ®ADAM9-directed...
MacroGenics Announces Leadership Transition
30 oct. 2024 07h30 HE
|
MacroGenics, Inc.
Scott Koenig, M.D., Ph.D., to step down as President and CEOBoard to initiate search process to identify new CEO ROCKVILLE, MD, Oct. 30, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (NASDAQ:...
MacroGenics Announces Date of Third Quarter 2024 Financial Results Conference Call
29 oct. 2024 16h30 HE
|
MacroGenics, Inc.
ROCKVILLE, MD, Oct. 29, 2024 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative antibody-based...
EpimAb Biotherapeutics Announces Upcoming Presentations at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
10 oct. 2024 21h00 HE
|
Shanghai EpimAb Biotherapeutics Co., Ltd.
SHANGHAI, Oct. 11, 2024 (GLOBE NEWSWIRE) -- EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies and T-cell engagers, is pleased to...
Distinguished Oncologist, Professor Daniel Von Hoff joins the Scientific/Clinical Advisory Board of EnGeneIC Cancer Therapeutics
01 oct. 2024 08h00 HE
|
EnGeneIC
EnGeneIC appoints Dr. Daniel Van Hoff to its Scientific Advisory Board to advise on clinical oncology programs, including upcoming PDAC trial.